Quantitative analysis of volatile organic compounds released and consumed by rat L6 skeletal muscle cells in vitro

Paweł Mochalski¹, Ramona Al-Zoairy², Andreas Niederwanger³, Karl Unterkofler¹,⁴ and Anton Amann¹,⁵

¹ Breath Research Institute of the University of Innsbruck, Rathausplatz 4, A-6850 Dornbirn, Austria
² Univ.-Clinic for Internal Medicine, Innsbruck Medical University, Anichstr. 35, A-6020 Innsbruck, Austria
³ Anzengruberstraße 1, A-6020 Innsbruck, Austria
⁴ Vorarlberg University of Applied Sciences, Hochschulstr. 1, A-6850 Dornbirn, Austria
⁵ Univ.-Clinic for Anesthesia and Intensive Care, Innsbruck Medical University, Anichstr. 35, A-6020 Innsbruck, Austria

E-mail: pawel.mochalski@uibk.ac.at and anton.amann@i-med.ac.at

Received 18 July 2014, revised 21 August 2014
Accepted for publication 21 August 2014
Published 13 October 2014

Abstract

Knowledge of the release of volatile organic compounds (VOCs) by cells provides important information on the origin of VOCs in exhaled breath. Muscle cells are particularly important, since their release of volatiles during the exertion of an effort contributes considerably to breath concentration profiles. Presently, the cultivation of human skeletal muscle cells is encountering a number of obstacles, necessitating the use of animal muscle cells in in vitro studies. Rat L6 skeletal muscle cells are therefore commonly used as a model for studying the molecular mechanisms of human skeletal muscle differentiation and functions, and facilitate the study of the origin and metabolic fate of the endogenously produced compounds observed in breath and skin emanations. Within this study the production and uptake of VOCs by rat L6 skeletal muscle cells were investigated using gas chromatography with mass spectrometric detection, combined with head-space needle trap extraction as the pre-concentration technique (HS-NTE-GC-MS). Seven compounds were found to be produced, whereas sixteen species were consumed (Wilcoxon signed-rank test, \( p < 0.05 \)) by the cells being studied. The set of released volatiles included two ketones (2-pentanone and 2-nonanone), two volatile sulphur compounds (dimethyl sulfide and methyl 5-methyl-2-furyl sulphide), and three hydrocarbons (2-methyl 1-propene, n-pentane and isoprene). Of the metabolized species there were thirteen aldehydes (2-propenal, 2-methyl 2-propenal, 2-methyl propanal, 2-butenal, 2-methyl butanal, 3-methyl butanal, n-pentanal, 2-methyl 2-butenal, n-hexanal, benzaldehyde, n-octanal, n-nonanal and n-decanal), two esters (n-propyl propionate and n-butyl acetate), and one volatile sulphur compound (dimethyl disulfide). The possible metabolic pathways leading to the uptake and release of these compounds by L6 cells are proposed and discussed. An analysis of the VOCs showed them to have huge potential for the identification and monitoring of some molecular mechanism and conditions.

Keywords: L6 cells, skeletal muscle, volatile organic compounds, uptake of VOCs, release of VOCs, enzyme expression

(Some figures may appear in colour only in the online journal)
1. Introduction

Over the last few decades, volatile organic compounds (VOCs) released by living organisms have provided invaluable information on the normal and disease processes occurring in an individual, as well as environmental exposure to pollutants/tobacco, or microorganisms’ activity in the body [1–10]. In the biomedical context, this specific chemical profile can be regarded as a versatile non-invasive tool having huge potential in diagnosis and therapeutic monitoring. The main unresolved issue limiting the use of this chemical fingerprint in biomedical applications is a poor understanding of the origin and metabolic fate of its constituents and the restricted knowledge on the partition of the volatile compounds into different compartments of the body [8, 11, 12]. This gap in our knowledge has stimulated extensive research in this exciting field. In vitro studies involving pathogenic microorganisms (bacteria, fungi), or cell cultures are, in this context, invaluable models for studying volatile biomarker production, and/or metabolism in human and animal organisms. For instance, over the last few years a substantial effort has been made to identify the volatiles released, or consumed by human normal and cancer cells [10, 13–17], bacteria [18, 19] or fungi [20]. Altogether, 75 volatile compounds in the head-space of cell cultures have been identified by their spectral library match and retention time [21]. Of these compounds, 62 have also been observed in exhaled breath, 33 in saliva, 22 in skin emanations, 21 in blood, 31 in urine and 48 in faeces [6]. We therefore expect that the compounds released by cells are of great importance for the exploration and understanding of endogenously produced compounds in exhaled breath and other body emanations.

Within the current study, L6 skeletal muscle cells were investigated. These cells were isolated from the primary cultures of rat thigh muscle, and are commonly used to explore the molecular mechanisms of muscle differentiation and function [22, 23]. The uptake and release of volatiles by skeletal muscle tissue can notably influence the VOC profiles observed in the breath, urine, or skin emanations of animals and humans. Hence, the main goal of this work is to identify and quantify the VOCs being emitted or consumed by differentiated L6 skeletal muscle cells. For this purpose gas chromatography with mass spectrometric detection (GC-MS) and head-space needle trap extraction (HS-NTE) as the pre-concentration method were applied.

2. Materials and methods

2.1. Chemicals and calibration mixtures

Multi-compound calibration mixtures were prepared from liquid substances. The reference substances with purities ranging from 95% to 99.9% were purchased from Sigma-Aldrich (Austria), CHEMOS GmbH (Germany), SAFC (Austria), Merck Schuchardt (Germany) and Fluka (Switzerland). Gaseous humid calibration mixtures were prepared using the procedure described in our recent article [17]. Humid gas mixtures (100% RH at 37 °C) with volume fractions ranging from 0.05 to 700 ppb were used for the purpose of calibration and validation. The calibration curves were obtained on the basis of two-fold analyses of six distinct concentration levels.

2.2. Cell cultivation

The L6 rat skeletal muscle cell line was obtained from ATCC (Manassas, VA, USA). The α-MEM was purchased from Sigma (St Louis, MO, USA), whereas, the FCS was from Biochrom AG (Berlin, Germany). The fatty acid/insulin-free BSA was obtained from Sigma (St Louis, MO, USA). The L6 skeletal muscle cells were cultured at 37 °C with 5% CO2 and used up to the ninth passage. Cells were grown in the α-MEM containing 10% FCS. The experiments were performed with fully differentiated myotubes 12–14 days post-confluency. The glass cultivation/measurement bottles (Ruprechter, Austria) had diameters of 21 cm × 5.5 cm × 11.5 cm (1000 ml nominal volume, and a bottom area of approximately 240 cm²). Their detailed description can be found in our recent article [17]. In total, eight experiments (involving cell cultures and controls) were performed.

2.3. Sampling procedure and chromatographic analysis

Head-space gas sampling, needle trap extraction, and the chromatographic analysis itself were performed in analogy with the procedures as outlined by Mochalski et al [17]. It should be stressed that the identification of the volatiles was performed in two steps. First, the peak spectrum was checked against the NIST mass spectral library. Next, the NIST identification was validated by comparing the respective retention times with the library of retention times obtained on the basis of the analyses of the standard mixtures. The peak integration was based on extracted ion chromatograms. The quantification ions used for the integration and retention times of the compounds in this study are listed in table 1.

3. Results and discussion

3.1. Validation parameters

The obtained validation parameters are presented in table 1. The limits of detection (LODs) were calculated using the algorithm presented by Huber [24]. More specifically, a standard deviation of nine consecutive blank signals and a 1% probability (1 − α) for a type 1 error resulting in a coverage factor of 3.05 were used for these purposes. The LOD values varied from 0.03 ppb for 2-methyl 2-propenal to 0.4 ppb for n-nonanal. The limit of quantification (LOQ) was defined as 3 × LOD. The relative standard deviations (RSDs) were calculated on the basis of the consecutive analyses of five independent standard mixtures exhibiting concentrations close to the medians of the observed levels in the head-space of the cell cultures (released VOCs), or the controls (consumed VOCs). The calculated RSDs ranged from 4–13% and were recognized as adequate for the goals of this study. The system response was found to be linear within the investigated concentration ranges with the coefficients of variation ranging from 0.93 to 0.999.
3.2. VOCs metabolized by L6 cells

A total of 16 species were found to be metabolized by L6 cells (Wilcoxon signed-rank test, \( p < 0.05 \)). Their detection and quantification incidences and concentrations in the head-space of cell cultures and controls are shown in table 2. The predominant chemical family within this set of volatiles were aldehydes (13 compounds). Apart from them, there were also two esters (n-propyl propionate and n-butyl acetate) and one volatile sulphur compound (dimethyl disulfide). The 2-methyl butanal could not be properly quantified due to its poor separation from the 3-methyl butanal and the absence of a unique ion that could be used for this purpose.

The uptake of aldehydes has been frequently observed in human cell cultures (both normal and cancerogenous) \([13, 14, 17]\) and attributed to the expression of aldehyde dehydrogenases (ALDHs) irreversibly oxidizing a wide spectrum of endogenous and exogenous aldehydes into their corresponding carboxylic acids \([25, 26]\). Indeed, ALDHs are also well expressed in the skeletal muscle tissue of both rats \([27]\) and humans \([28–30]\), and could thereby be responsible for the observed change in the aldehyde level. An alternative pathway leading to the consumption of aldehydes by L6 cells involves alcohol dehydrogenases (ADHs). ADHs reversibly reduce aldehydes to alcohols, and were found to be present in rat skeletal muscle tissue \([31]\). However, the drastic drop in alkanal concentrations (the preferred substrates for ALDHs \([26]\)) suggests that aldehyde dehydrogenases are a more plausible reason for aldehyde uptake.

The decrease in the n-propyl propionate and n-butyl acetate levels in the head-space of the cultivation bottles could have been a reflection of the activity of carboxylesterases (CESs), a class of enzymes present in human and rat skeletal muscles \([32–34]\). The main function of CESs is the hydrolysis of esters into carboxylic acids and alcohols. Consequently, these enzymes could hydrolyse n-butyl acetate into acetic acid and 1-butanol, and n-propyl propionate into propanoic acid and 1-propanol. The alcohol products of these reactions can be subsequently converted into the respective carboxylic acids by ADHs and ALDHs. The analogous uptake of esters has been documented in human liver and lung cells \([13–15, 17]\), which also exhibit high CES expression \([34]\).

The metabolic pathway leading to the dimethyl disulfide degradation by L6 cells remains unclear.

### Table 1. Retention times \( R_t \) (min), quantifier ions, LODs (ppb), RSDs (%), coefficients of variation \( R^2 \), and linear ranges (ppb) of compounds under study. The compounds are ordered with respect to the increasing retention time.

| VOC                          | CAS            | \( R_t \) (min) | Quantifier ion | LOD (ppb) | RSD (%) | \( R^2 \) | Linear range (ppb) |
|------------------------------|----------------|-----------------|----------------|-----------|---------|-----------|-------------------|
| 1-Propene, 2-methyl-         | 115-11-7       | 12.92           | 56             | 0.05      | 7       | 0.999     | 0.15–14           |
| 2-Propenal                   | 107-02-8       | 15.03           | 56             | 0.13      | 4       | 0.998     | 0.4–51            |
| Dimethyl sulfide             | 75-18-3        | 16.35           | 62             | 0.08      | 6       | 0.997     | 0.24–70           |
| Isoprene                     | 78-79-5        | 18.18           | 67             | 0.04      | 4.5     | 0.999     | 0.12–12           |
| n-Pentane, 2-methyl-         | 109-66-0       | 18.55           | 43             | 0.3       | 6       | 0.999     | 0.9–19.5          |
| 2-Propenal, 2-methyl-        | 78-85-3        | 19.11           | 70             | 0.03      | 8       | 0.993     | 0.1–12            |
| Propanal, 2-methyl-          | 78-84-2        | 19.43           | 72             | 0.3       | 9       | 0.977     | 0.9–150           |
| 2-Butenal, (E)-              | 123-73-9       | 21.53           | 70             | 0.14      | 9       | 0.978     | 0.4–700           |
| Butanal, 3-methyl-           | 590-86-3       | 23.48           | 44             | 0.05      | 7       | 0.998     | 0.15–9            |
| n-Propylene                  | 107-87-9       | 24.10           | 43             | 0.25      | 8       | 0.975     | 0.75–10           |
| n-Pentanal                   | 110-62-3       | 24.30           | 58             | 0.04      | 9       | 0.999     | 0.12–11           |
| Dimethyl disulfide           | 624-92-0       | 24.74           | 94             | 0.04      | 9       | 0.999     | 0.12–6.5          |
| 2-Butenal, 2-methyl-         | 1115-11-3      | 24.93           | 84             | 0.04      | 9       | 0.999     | 0.12–6.5          |
| n-Hexanal                    | 66-25-1        | 27.38           | 56             | 0.2       | 9       | 0.994     | 0.6–30            |
| n-Propyl propionate          | 106-36-5       | 28.11           | 75             | 0.03      | 10      | 0.996     | 0.1–28            |
| n-Butyl acetate              | 123-86-4       | 28.27           | 56             | 0.04      | 10      | 0.997     | 0.12–42           |
| Benzaldehyde                 | 100-52-7       | 30.99           | 106            | 0.05      | 12      | 0.998     | 0.15–12           |
| Methyl 5-methyl-2-furyl sulfide | 13678-59-6   | 31.05           | 128            | 0.03      | 7       | 0.988     | 0.09–4            |
| n-Octanal                    | 124-13-0       | 33.76           | 84             | 0.1       | 10      | 0.993     | 0.3–13            |
| 2-Nonanone                   | 821-55-6       | 36.25           | 58             | 0.07      | 11      | 0.974     | 0.21–2.8          |
| n-Nonanal                    | 124-19-6       | 36.41           | 57             | 0.4       | 12      | 0.930     | 1.2–12            |
| n-Decanal                    | 112-31-2       | 39.57           | 82             | 0.25      | 13      | 0.962     | 0.7–13            |

3.3. VOCs released by L6 cells

Seven compounds were found to be liberated by L6 muscle cells (see table 2). Among them there were two ketones (2-pentanone and 2-nonanone), three hydrocarbons (2-methyl 1-propene, isoprene and n-pentane) and two volatile sulfur compounds (dimethyl sulphide and methyl 5-methyl-2-furyl sulphide). All these compounds have been observed in some human matrices \([6]\). Specifically, methyl 5-methyl-2-furyl sulfide has been observed in urine head-space.

Two potential pathways could be involved in ketone production by the cells in this study: (i) the oxidation of secondary alcohols catalysed by ADHs and (ii) the \( \beta \)-oxidation of branched-chain fatty acids. ADHs are major enzymes responsible for ethanol metabolism; however, they can also oxidize long-chain, cyclic and secondary alcohols \([25, 35]\). If so, 2-pentanone could stem from 2-pentanol, whereas, 2-nonanone could derive from 2-nonanol. The source of these
secondary alcohols remains unclear. Perhaps they were constituents of the applied medium, or stemmed from the metabolism of the n-alkanes. For instance, 2-nonanol could be the source of several ketones in humans. For example, 3-heptanone [39]. The branched-chain fatty acids could be a product of n-nonane oxidation catalysed by cytochrome P450. Indeed, n-heptane is transformed into isoprene enzymatically by isoprene synthase [45, 50], whereas in animals and humans it has been unlikely to explain the high isoprene levels in humans [43]. Moreover, emerging evidence provided by a number of recent studies suggests that other endogenous metabolic sources may contribute to isoprene formation in the human organism [52–54]. Isoprene has received widespread attention in the field of breath gas analysis due to the fact that it may serve as a marker for various pathological conditions.

Table 2. The detection (n_d) and quantification (n_q) incidences, concentration ranges, and medians of VOCs in this study in the head-space of media and cell cultures.

| VOC                  | CAS          | Incidence | Cell cultures | Medium | Wilcoxon signed-rank test p |
|----------------------|--------------|-----------|---------------|--------|-----------------------------|
| Uptake               |              |           |               |        |                             |
| 2-Propenal           | 107-02-8     | 8(8)      | 2.42–15.8 (5.83) | 8(8)   | 12.3–43.7 (14.4) | 0.00782 |
| 2-Propenal, 2-methyl-| 78-85-3      | 8(8)      | 0.28–1.44 (0.6) | 8(8)   | 2.26–8.66 (3.16) | 0.00782 |
| Propanal, 2-methyl-  | 78-84-2      | 8(5)      | 1.55–4.44 (1.72) | 8(8)   | 42.6–227 (85.27) | 0.00782 |
| 2-Butanone, (E)-     | 113-73-9     | 8(8)      | 413–959 (626)   | 8(8)   | 4160–11220 (8674) | 0.00782 |
| Butanal, 3-methyl-   | 590-86-3     | 8(8)      | 0.52–17.5 (6.68) | 8(8)   | 551–1590 (1145) | 0.00782 |
| n-Pentanal           | 110-62-3     | 8(4)      | 0.77–11 (0.94)  | 8(8)   | 4.04–8.57 (6.7)  | 0.03907 |
| Dimethyl disulphide  | 624-92-0     | 8(8)      | 0.14–0.5 (0.24) | 8(8)   | 1.15–4.23 (3.35) | 0.00782 |
| 2-Butenol, 2-methyl- | 1171-15-3    | 1(0)      | n.q.           | 8(8)   | 0.13–7.2 (1.82)  | 0.00782 |
| n-Hexanal            | 66-25-1      | 8(4)      | 0.63–1.34 (0.68) | 8(8)   | 17.1–36.7 (29.8) | 0.00782 |
| n-Propyl propionate  | 106-36-5     | 8(8)      | 0.15–8.56 (1.18) | 8(8)   | 1.0–18.4 (2.27)  | 0.00782 |
| n-Butyl acetate      | 123-86-4     | 8(8)      | 0.21–33.2 (1.94) | 8(8)   | 6.87–46 (40)     | 0.00782 |
| Benzaldehyde         | 100-52-7     | 8(7)      | 0.20–0.53 (0.29) | 8(8)   | 1.92–3.49 (2.69) | 0.00782 |
| n-Octanal            | 124-13-0     | 6(0)      | n.q.           | 8(8)   | 0.97–7.77 (1.49) | 0.00782 |
| n-Nonanal            | 124-19-6     | 8(7)      | n.d.           | 8(8)   | 1.38–3.22 (2.0)  | 0.00782 |
| n-Decanal            | 112-31-2     | 8(7)      | 0.85–2.19 (1.01) | 8(8)   | 1.92–10.8 (4.45) | 0.00782 |
| Release              |              |           |               |        |                             |
| 1-Propene, 2-methyl- | 115-11-7     | 8(8)      | 2.41–11.4 (5.68) | 8(8)   | 2.33–5.20 (3.05)  | 0.03907 |
| Dimethyl sulphide    | 75-18-3      | 8(8)      | 1.50–11.2 (6.37) | 8(8)   | 0.29–0.83 (0.32)  | 0.00782 |
| Isoprene             | 78-79-5      | 8(8)      | 0.23–0.57 (0.44) | 8(8)   | 0.14–0.68 (0.26)  | 0.03907 |
| n-Pentane            | 109-66-0     | 8(8)      | 2.76–9.29 (5.14) | 8(8)   | 2.4–5.4 (3.2)    | 0.0157  |
| 2-Pentanone          | 107-87-9     | 8(8)      | 1.17–2.25 (1.38) | 8(8)   | 0.47–1.03 (0.87) | 0.00782 |
| Methyl 5-methyl-2-furyl| 13678-59-6   | 8(7)      | 0.14–0.25 (0.18) | 3(0)   | n.q.             | 0.00782 |
| sulfide              | 821-55-6     | 8(7)      | 0.27–0.5 (0.34) | 8(0)   | n.q.             | 0.0157  |

Note. The compounds in italics were not quantified for reasons mentioned in the text; n.d.—not detected (<LOD), n.q.—not quantified (<LOQ).
as a sensitive, non-invasive indicator for assaying several metabolic effects in the human body [47, 55]. Consequently, its sources and sinks in humans are of particular importance for its application in diagnosis and therapy monitoring. The release of isoprene by rat L6 muscle cells supports the hypothesis of the extra-hepatic production of this hydrocarbon in humans [52]. Although the observed isoprene emission was relatively small, it should be remembered that the levels of isoprene in rats are markedly lower than those in humans [46].

The release of n-pentane might mirror oxidative stress inducing the peroxidation of unsaturated fatty acids. The lipid peroxidation of ω3 and ω6 fatty acids was demonstrated to generate some saturated hydrocarbons, such as ethane and n-pentane in numerous animal and human studies [56–60]. More specifically, ethane and n-pentane are generated via the β-scission of alkoxy radicals formed by the homolytic cleavage of fatty acids hydroperoxides. In vitro studies provided evidence of the production of n-pentane from linoleic and arachidonic acids [56, 61, 62]. This hypothesis is consistent with numerous studies, suggesting an oxidative stress condition in both contracting and inactive skeletal muscles [63, 64]. In particular, extended periods of skeletal muscle inactivity seem to promote the production of reactive oxygen species (ROS), which in turn contribute to increased proteolysis and inactivity-induced oxidative injury [63]. Although the exact production pathways of ROS in inactive skeletal muscles are still a matter in dispute, the use of exogenous antioxidants delays the atrophy of this tissue [63]. Hence, n-pentane released by the L6 cells seems to additionally confirm oxidative stress in skeletal muscles during disuse and could be considered as a marker of this load. In this context, the isoprene produced by the skeletal muscle cells could offer protection against oxidative stress analogously, as is hypothesized in plant physiology [65]. This strongly evidenced theory states that in plants, isoprene acts as an ROS sweeper reacting with radicals through the double bond system.

4. Conclusions

The objective of this study was to identify volatile organic compounds metabolized and produced by rat L6 skeletal muscle cells—a cell line commonly used to explore the molecular mechanisms of muscle differentiation and function. Twenty-three VOCs were found to change their levels in the presence of L6 cells. Among them 16 compounds were metabolized and a further seven released. The uptake and production of these species might be attributed to several metabolic pathways, or conditions, such as the expression of enzymes (ADHs, ALDHs, CESs or thiol S-methyltransferase), or oxidative stress. Hence, the analysis of VOC profiles in cell cultures could be considered as a powerful tool capable of revealing the metabolic functions of enzymes, tracking their activities and detecting other normal and abnormal cellular conditions. Moreover, the VOC profiles of cell cultures can provide invaluable input into the elucidation of the origin and metabolic fate of numerous volatiles, and thereby contribute to their application in medical diagnosis and therapeutic monitoring. The findings of this study are expected to contribute to the expansion of knowledge of the volatile biomarkers released by animals and humans.

Acknowledgments

We gratefully appreciate the funding from the Oncotyrol-project 2.1.1. The Competence Centre Oncotyrol is funded within the scope of COMET—Competence Centers for Excellent Technologies through BMVIT, BMWFW, through the province of Salzburg and the Tiroler Zukunftsforschung/Standortagentur Tirol. The COMET Program is conducted by the Austrian Research Promotion Agency (FFG). PM and KU gratefully acknowledge support from the Austrian Science Fund (FWF) under Grant No P24736-B23. We appreciate the funding by the Scientific and Technological Cooperation (Wissenschaftlich-Technische Zusammenarbeit—WTZ) between Austria and Poland (project no PL 02/2012). We thank the government of Vorarlberg (Austria) for its generous support.

References

[1] Amann A and Smith D 2005 Breath Analysis for Clinical Diagnosis and Therapeutic Monitoring (Singapore: World Scientific)
[2] Amann A and Smith D 2013 Volatile Biomarkers Non-Invasive Diagnosis in Physiology and Medicine ed A Amann and D Smith (Amsterdam: Elsevier)
[3] Horvath I and de Jongste J E 2010 Exhaled Biomarkers (European Respiratory Monograph no 49) (Plymouth, UK: European Respiratory Society)
[4] Mochalski P, King J, Haas M, Unterkofler K, Amann A and Mayer G 2014 Blood and breath profiles of volatile organic compounds in patients with end-stage renal disease BMC Nephrol. 15 43
[5] Mochalski P, King J, Klieber M, Unterkofler K, Hinterhuber H, Baumann M and Amann A 2013 Blood and breath levels of selected volatile organic compounds in healthy volunteers Analyst 138 2134–45
[6] de Lacy Costello B, Amann A, Al-Kateb H, Flynn C, Filipiak W, Khalid T, Osborne D and Ratcliffe N M 2014 A review of the volatiles from the healthy human body J. Breath Res. 8 014001
[7] Amann A, Mochalski P, Ruzsanyi V, Broza Y Y and Haick H 2014 Assessment of the exhalation kinetics of volatile cancer biomarkers based on their physicochemical properties J. Breath Res. 8 016003
[8] Haick H, Broza Y Y, Mochalski P, Ruzsanyi V and Amann A 2014 Assessment, origin, and implementation of breath volatile cancer markers Chem. Soc. Rev. 43 1423–49
[9] Amann A, Miekisch W, Schubert J, Buszewski B, Ligor T, Jezierski T, Pleij J and Risby T 2014 Analysis of exhaled breath for disease detection Annu. Rev. Anal. Chem. 7 455–82
[10] Filipiak W et al 2014 Comparative analyses of volatile organic compounds (VOCs) from patients, tumors and transformed cell lines for the validation of lung cancer-derived breath markers J. Breath Res. 8 027111
[11] Mochalski P, King J, Kupferthaler A, Unterkofler K, Hinterhuber H and Amann A 2011 Measurement of isoprene solubility in water, human blood and plasma by multiple headspace extraction gas chromatography coupled with solid phase microextraction J. Breath Res. 5 046010
[12] Mochalski P, King J, Kupferthaler A, Unterkofler K, Hinterhuber H and Amann A 2012 Human blood and plasma partition coefficients for C4–C8 n-alkanes, isokanelks, and 1-alkanes Int. J. Toxicol. 31 267–75

[13] Filipiak W, Sponring A, Filipiak A, Cager C, Schubert J, Miekisch W, Amann A and Tropm Johann J 2010 TD-GC-MS analysis of volatile metabolites of human lung cancer and normal cells in vitro Cancer Epidemiol. Biomarkers Prev. 19 182–95

[14] Filipiak W, Sponring A, Mikoviny T, Ager C, Schubert J, Miekisch W, Amann A and Tropm Johann J 2008 Release of volatile organic compounds (VOCs) from the lung cancer cell line CALU-1 in vitro Cancer Cell Int. 8 17

[15] Sponring A, Filipiak W, Ager C, Schubert J, Miekisch W, Amann A and Tropm Johann J 2010 Analysis of volatile organic compounds (VOCs) in the headspace of NCI-H1666 lung cancer cells Cancer Biomarkers 7 153–61

[16] Sponring A, Filipiak W, Mikoviny T, Ager C, Schubert J, Miekisch W, Amann A and Tropm Johann J 2009 Release of volatile organic compounds from the lung cancer cell line NCI-H2087 in vitro Anticancer Res. 29 419–26

[17] Mochalski P, Sponring A, King J, Unterkofler K, Tropm Johann J and Amann A 2013 Release and uptake of volatile compounds by human hepatocellular carcinoma cells (HepG2) in vitro Cancer Cell Int. 13 72

[18] Filipiak W, Sponring A, Baur M M, Ager C, Filipiak A, Wiesenhofer H, Nagl M, Tropm Johann J and Amann A 2012 Characterization of volatile metabolites taken up by or released from Streptococcus pneumoniae and Haemophilus influenzae by using GC-MS Microbiology 158 (Part 12) 3044–53

[19] Filipiak W, Sponring A, Baur M M, Filipiak A, Ager C, Wiesenhofer H, Nagl M, Tropm Johann J and Amann A 2012 Molecular analysis of volatile metabolites released specifically by Staphylococcus aureus and Pseudomonas aeruginosa BMC Microbiol. 12 113

[20] Filipiak W, Sponring A, Filipiak A, Baur M, Ager C, Wiesenhofer H, Margesin R, Nagl M, Tropm Johann J and Amann A 2013 Volatile organic compounds (VOCs) released by athogenic microorganisms in vitro: potential breath biomarkers for early-stage diagnosis of disease Volatile Biomarkers: Non-Invasive Diagnosis in Physiology and Medicine ed A Amann (Amsterdam: Elsevier)

[21] Calenc B, Filipiak W, Greaeb M and Amann A 2013 Volatile organic compounds expression in different cell types an in vitro approach Int. J. Clin. Toxicol. 1 43–51

[22] Yuzefovych L V, LeDoux S P, Wilson G L and Rachek L I 2013 Mitochondrial DNA damage via augmented oxidative stress regulates endoplasmic reticulum stress and autophagy: crosstalk, links and signaling J. Breath Res. 7 42–6

[23] Kranbitter M, Niederwanger A, Tatarczyk T, Ciardi C, Al-Zoairy R, Patsch J R and Pedrini M T 2010 Pioglitazone has direct effects on insulin sensitivity and intracellular lipid content in L6 skeletal muscle cells Horm. Metab. Res. 42 987–90

[24] Huber W 2003 Basic calculations about the limit of detection and its optimal determination Accreditation Qual. Assur. 8 215–17

[25] Crabb D W, Matsumoto M, Chang K and You M 2004 Overview of the role of alcohol dehydrogenase and aldehyde dehydrogenase and their variants in the genetics of alcohol-related pathology Proc. Natl. Acad. Sci. 63 49–63

[26] Klyosov A A 1996 Kinetics and specificity of human liver aldehyde dehydrogenases toward aliphatic, aromatic, and fused polycyclic aldehydes Biochemistry 35 4457–67

[27] Nilsson E G 1988 A comparative study of aldehyde dehydrogenase and alcohol dehydrogenase activities in crucian carp and three other vertebrates: apparent adaptations to ethanol production J. Comput. Physiol. B 158 479–85

[28] Stewart M J, Malek K and Crab D W 1996 Distribution of messenger RNAs for aldehyde dehydrogenase 1, aldehyde dehydrogenase 2, and aldehyde dehydrogenase 5 in human tissues J. Investig. Med. 44 42–6

[29] Sladek N E 2003 Human aldehyde dehydrogenases: potential pathological, pharmacological, and toxicological impact J. Biochem. Mol. Toxicol. 17 7–23

[30] Jean E, Laoudji-Chenivesse D, Notarnicola C, Rouger K, Serratrice N, Bonnec A, Gay S, Baco D, Duret C and Camac G 2011 Aldehyde dehydrogenase activity promotes survival of human muscle precursor cells J. Cell. Mol. Med. 15 119–33

[31] Julia P, Farres J and Pares X 1987 Characterization of three isoenzymes of rat alcohol dehydrogenase, Tissue distribution and physical and enzymatic properties Eur. J. Biochem. 162 179–89

[32] Mendoza C E, Shields J B and Phillips W E 1971 Distribution of carboxylesterase activities in different tissues of albino rats Comput. Biochem. Physiol. B 40 841–54

[33] Satoh T and Hosokawa M 1998 The mammalian carboxylesterases: from molecules to functions Ann. Rev. Pharmacol. Pharmacocinet. 38 257–88

[34] Imai T 2006 Human carboxylesterase isozymes: catalytic properties and rational drug design Drug Metab. Pharmacokinet. 21 173–85

[35] Ditlow C, Holmqvist B, Morelock M M and Valle B L 1984 Physical and enzymatic properties of a class II alcohol dehydrogenase isozyme of human liver: pi-ADH Biochemistry 23 6363–8

[36] Serve M P, Bombick D D, Baugham T M, Jarnot B, M, Ketcha M and Mattie R D 1995 The metabolism of n-nonane in male Fischer-344 rats Chemosphere 31 2661–8

[37] Edwards J E, Rose R L and Hodgson E 2005 The metabolism of nonane, a JP-8 jet fuel component, by human liver microsomes, P450 isoforms and alcohol dehydrogenase and inhibition of human P450 isoforms by JP-8 Chem. Biol. Interact. 151 203–11

[38] Erhart S et al 2009 3-Heptane as a potential new marker for valproic acid therapy J. Breath Res. 3 016004

[39] Walker V and Mills G A 2001 Urine 4-heptanone: a beta-oxidation product of 2-ethylhexanoic acid from plasticisers Clin. Chim. Acta 306 51–61

[40] Hanai Y, Shimomo K, Oka H, Baba Y, Yamazaki K and Beauchamp G K 2012 Analysis of volatile organic compounds released from human lung cancer cells and from the urine of tumor-bearing mice Cancer Cell Int. 12 7

[41] Tangerman A 2009 Measurement and biological significance of the volatile sulfur compounds hydrogen sulfide, methanethiol and dimethyl sulfide in various biological matrices J. Chromatogr. B 877 3636–77

[42] Velikova V B 2008 Isoprene as a tool for plant protection against abiotic stresses. J. Plant Interact. 3 1–15

[43] Sharkey T D and Yeh S 2001 Isoprene emission from plants Annu. Rev. Plant Physiol. Plant Mol. Biol. 52 407–36

[44] Wagner W P, Helmig D and Fall R 2000 Isoprene biosynthesis in Bacillus subtilis via the methylerythritol phosphate pathway J. Nat. Prod. 63 87–90

[45] Fall R and Copley S D 2000 Bacterial sources and sinks of isoprene, a reactive atmospheric hydrocarbon Environ. Microbiol. 2 123–30

[46] Cailleux A, Cogny M and Allain P 1992 Blood isoprene concentrations in humans and in some animal species Biochem. Med. Metab. Biol. 47 157–60

[47] Kushch et al 2008 Breath isoprene—aspects of normal physiology related to age, gender and cholesterol profile as determined in a proton transfer reaction mass spectrometry study Clin. Chem. Lab. Med. 46 1011–8
[48] Rasmussen L E and Perrin T E 1999 Physiological correlates of musth: lipid metabolites and chemical composition of exudates Physiol. Behav. 67 539–49
[49] Jomaa H et al 1999 Inhibitors of the nonmevalonate pathway of isoprenoid biosynthesis as antimalarial drugs Science 285 1573–6
[50] Silver G M and Fall R 1991 Enzymatic synthesis of isoprene from dimethylallyl diphosphate in aspen leaf extracts Plant Physiol. 97 1588–91
[51] Deneris E S, Stein R A and Mead J F 1985 Acid-catalyzed formation of isoprene from a mevalonate-derived product using a rat liver cytosolic fraction J. Biol. Chem. 260 1382–5
[52] King J, Mochalski P, Unterkofler K, Teschl G, Klieber M, Stein M, Amann A and Baumann M 2012 Breath isoprene: muscle dystrophy patients support the concept of a pool of isoprene in the periphery of the human body Biochim. Biophys. Res. Commun. 423 526–30
[53] McGrath L T, Patrick R and Silke B 2001 Breath isoprene in patients with heart failure Eur. J. Heart Fail. 3 423–7
[54] King J, Koc H, Unterkofler K, Mochalski P, Kupferthaler A, Teschl G, Teschl S, Hinterhuber H and Amann A 2010 Physiological modeling of isoprene dynamics in exhaled breath J. Theor. Biol. 267 626–37
[55] Salerno-Kennedy R and Cashman K D 2005 Potential applications of breath isoprene as a biomarker in modern medicine: a concise overview Wien Klin. Wochenschr. 117 180–6
[56] Kneepkens C M, Lepage G and Roy C C 1994 The potential of the hydrocarbon breath test as a measure of lipid peroxidation Free Radic. Biol. Med. 17 127–60
[57] Phillips M, Catanese R N, Greenberg J, Grodman R, Gunawardena R and Naidu A 2003 Effect of oxygen on breath markers of oxidative stress Eur. Respir. J. 21 48–51
[58] Aghdassi E, Wendland B E, Steinhart A H, Wolman S L, Jeejeebhoy K and Allard J P 2003 Antioxidant vitamin supplementation in Crohn’s disease decreases oxidative stress. A randomized controlled trial Am. J. Gastroenterol. 98 348–53
[59] Aghdassi E and Allard J P 2000 Breath alkanes as a marker of oxidative stress in different clinical conditions Free Radic. Biol. Med. 28 880–6
[60] Dillard C J, Dumelin E E and Tappel A L 1977 Effect of dietary vitamin E on expiration of pentane and ethane by the rat Lipids 12 109–14
[61] Dumelin E E and Tappel A L 1977 Hydrocarbon gases produced during in vitro peroxidation of polyunsaturated fatty acids and decomposition of preformed hydroperoxides Lipids 12 894–900
[62] Frankel E N 1980 Lipid oxidation Prog. Lipid Res. 19 1–22
[63] Powers S K, Kavazis A N and McClung J M 1985 Oxidative stress and disuse muscle atrophy J. Appl. Physiol. 102 2389–97
[64] Kondo H, Nakagaki I, Sasaki S, Hori S and Itokawa Y 1993 Mechanism of oxidative stress in skeletal muscle atrophied by immobilization Am. J. Physiol. 265 (Part 1) E839–44
[65] Vickers C E, Gershenzon J, Lerdau M T and Loreto F 2009 A unified mechanism of action for volatile isoprenoids in plant abiotic stress Nature Chem. Biol. 5 283–91